Open-label, practice-based randomized trial of varenicline + Positively Smoke Free-Mobile (PSF-M) for people living with Human Immunodeficiency Virus (PWH) who smoke or use both smoked and smokeless tobacco compared with a group that receives standard care including brief advice and quitline referral.~Positively Smoke Free (PSF) is a behavioral intervention which has been tested in multiple formats including a mobile version. Varenicline is the single most-effective pharmacotherapy agent for quitting tobacco with demonstrated efficacy for cessation of cigarettes, smokeless tobacco, and cessation among smokers with comorbidities~In this study, participants will be randomized to either Group 1: Varenicline + Positively Smoke Free-Mobile adapted for Chennai versus Group 2: Standard care with brief tobacco cessation advice and referral to the national quitline.~Research procedures include screening for eligibility, in-clinic visits, and completion of surveys and questionnaires.~Participation in this study is expected to last about 24 weeks.~It is expected about 400 people will take part in this research study.~This study is funded by the National Cancer Institute of the National Institute of Health (NIH).
The goal of this research study is to test an intervention to help quit tobacco use in participants with Human Immunodeficiency Virus (HIV).~The study interventions used in this research study are:~Positively Smoke Free - Mobile (PSF-M) (mobile behavioral program)~Varenicline (or Chantix)